Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 4/20 | 0.61 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.61 |
| ▸ | TFPI | P10646 | 4/20 | 0.57 |
| ▸ | REN | P00797 | 4/20 | 0.57 |
| ▸ | NPY2R | P49146 | 4/20 | 0.56 |
| ▸ | NPY4R | P50391 | 4/20 | 0.56 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.56 |
| ▸ | NPY1R | P25929 | 3/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13234135 | 0.99 | AGTR1 (0.59) | AGTR1AGTR2TFPIRENNPY2R | |
| SCHEMBL13234138 | 0.98 | AGTR1 (0.59) | AGTR1AGTR2TFPIRENNPY2R | |
| SCHEMBL13234131 | 0.98 | AGTR1 (0.59) | AGTR1AGTR2TFPINPY2RNPY4R | |
| SCHEMBL13264037 | 0.95 | AGTR1 (0.56) | AGTR1AGTR2TFPINPY2RNPY4R | |
| SCHEMBL13197589 | 0.94 | AGTR1 (0.62) | AGTR1AGTR2TFPINPY2RNPY4R | |
| SCHEMBL13234141 | 0.89 | F2 (0.53) | AGTR1AGTR2 | |
| SCHEMBL13234128 | 0.85 | AGTR1 (0.69) | AGTR1AGTR2REN | |
| SCHEMBL32930844 | 0.84 | AGTR1 (0.70) | AGTR1AGTR2TFPIRENNPY2R | |
| SCHEMBL29778186 | 0.83 | AGTR2 (0.77) | AGTR1AGTR2TFPIRENNPY2R | |
| Angiotensin Ii SCHEMBL8898391 | 0.83 | AGTR2 (0.83) | AGTR1AGTR2REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7763234-B2 | Pharmaceutical compounds | GE HEALTHCARE AS (NO) | 2010-07-27 | — | — | US | disclosed |
| US-7763234-B2 | Pharmaceutical compounds | GE HEALTHCARE AS (NO) | 2010-07-27 | — | — | US | disclosed |
| US-20070297979-A1 | Pharmaceutical Compounds | GE HEALTHCARE AS (NO) | 2007-12-27 | — | — | US | disclosed |
| US-20070297979-A1 | Pharmaceutical Compounds | GE HEALTHCARE AS (NO) | 2007-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070297979-A1 | Pharmaceutical Compounds | FURIN, ACE, PEPD | AGTR1 38/4885AGTR2 51/4885TFPI 508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.